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  This paper presents a medical cost function developed for a screening programme. The 
medical cost function is a function of advancement both directly and indirectly through 
survival. We discuss how the medical cost function is affected by screening through a shift in 
the distribution of cancers according to advancement. We show that screening reduces the 
treatment cost for cancers diagnosed at the screening, even though the medical cost function 
not unambiguously increases with stage of advancement. This is the first step in a cost-
effectiveness analysis, and even though the results are favourable to the introduction of 
screening for colorectal cancer as a preventive health measure, total screening costs and health 
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  11. Introduction 
Analyses of health care interventions are now regarded as providing fundamental 
information for government decisions about resource allocation. Since resources are scarce, 
such decisions should be based on a thorough analysis of all the consequences of the 
intervention concerned.  
The aim of the present analysis is to investigate the relation between screening and 
colorectal treatment cost (CRTC). The CRTC function depends on two main factors: stage of 
advancement of the cancer and survival time. The stage of advancement affects the CRTC 
function both directly and indirectly, directly by the relation between the intensity of 
colorectal treatment and the stage of advancement, while indirectly by the relation between 
the stage of advancement and survival. The CRTC function is affected by increased survival 
as more treatment can be offered. The CRTC function is a positive function of advancement 
when the direct effect of stage of advancement on the CRTC function is positive and greater 
than the effect of advancement through survival.   
Screening results in early detection of asymptomatic cancers, i.e. cancers that on 
average are less advanced than cancers diagnosed as a result of symptoms. Thus screening 
implies a shift in the distribution of cancers towards less advanced cancers.      If  the  CRTC 
function is a positive function of advancement, screening will result in a reduction in the 
CRTC function. It is possible to compare CRTC for asymptomatic cancers and symptomatic 
cancers without including stage of advancement. By including stage of advancement we 
contribute to the explanation of the difference in CRTC for asymptomatic and symptomatic 
cancers.  
   We estimate CRTC as a function of advancement, building on the work of Etzioni et 
al. (2001). We assume that the individual never fully recovers from colorectal cancer, which 
means that the expected CRTC depends on the length of time the individual survives after the 
cancer diagnosis. Since we are not able to follow all individuals from the time of diagnosis 
until death and have different observation periods for each individual, the dataset is censored 
by the exit possibilities: death and the end of the dataset. To estimate expected CRTC, 
survival is used to adjust for censoring in the dataset. Independent of the stage of 
advancement, the survival probability is assumed to depend on individual characteristics of 
the patient, such as age and education.  
In Etzioni et al. (2001), Bleeker et al. (2001), Ramsey et al. (2002), Ramsey et al. 
(2003) and Brown et al. (2002), the survival distribution is analysed by the Kaplan-Meier 
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relevant individual characteristics are included simultaneously. In order to study the 
hypothesis that screening results in a reduction in CRTC function, we base the analysis on a 
randomized controlled trial (RCT).   
Based on the principle ‘intention to treat’, we compare with the control group the 
expected CRTC for all individuals invited to the screening, rather than only the expected 
CRTC for those actually participating in the screening. The invited group (total screening 
group) is divided into three subgroups on the basis of their participation status and time of 
diagnosis: 1) asymptomatic participants, 2) symptomatic participants and 3) non-participants. 
A RCT is not needed to compare expected CRTC for asymptomatic participants with 
expected CRTC in the control group. But with the RCT it is possible derive useful 
information by comparing expected CRTC in the total screening group and for different 
subgroups with expected CRTC in the control group, which yields results that not are 
analysed in Etzioni et al. (2001), Bleeker et al. (2001), Ramsey et al. (2002), Ramsey et al. 
(2003) and Brown et al. (2002). For instance, if the expected CRTC in the control group is 
higher than the expected CRTC for asymptomatic participants and lower than expected CRTC 
for non-participants, the findings could be explained by selection bias with regard to 
participation and not the fact that screening reduces stage of advancement.   
If the expected CRTC for an asymptomatic participant is lower than that for an 
individual in the control group, the potential cost savings of increasing participation will be 
considerable. If the expected CRTC is higher for a non-participant than for an individual in 
the control group, the potential cost savings of increasing participation will be even greater. 
The variation in the estimated expected CRTC due to differences in survival time is also 
captured in this analysis, but the expected CRTC may also vary as a result of, for instance, 
different practices between hospitals, uncertain cost estimates or the age of the patient. To 
give a realistic picture of the uncertainty of expected CRTC estimates we use both 
probabilistic sensitivity analysis (PSA) and the bootstrap method for calculating 95 percent 
confidence intervals. Brown et al. (2002) use bootstrapping, but to our knowledge no one has 
used PSA and compared it with the bootstrap method in the estimation of treatment cost.  
  The results show that the expected CRTC increases with the stage of advancement of 
colorectal cancer and that screening reduces future treatment costs. Hence, the results of this 
first step in the cost-effectiveness analysis are favourable to the introduction of screening for 
colorectal cancer as a preventive health measure. The reduction in future treatment costs is not 
supported by the PSA, since the confidence interval is large. The confidence interval 
  3calculated by the bootstrap method is narrower than that calculated by the PSA and does not 
invalidate the conclusion that screening is favourable to a reduction in the CRTC.    
  The paper is structured as follows. Section 2 is a description of screening and the 
treatment of colorectal cancer, and Section 3 presents the statistical methods used. Section 4 is 
a report of the data: 4.1 presents the data in the survival analysis and 4.2 the treatment cost 
data. Section 5 presents the results of the survival analysis and Section 6 the estimated CRTC 
and the uncertainty analyses. The sensitivity analysis is presented in Section 7 while we in 
Section 8 discuss the underlying assumptions on which the results are based.  
 
 
2. The colorectal treatment cost function 
The expected benefits from screening for colorectal cancer are a higher probability of 
not dying from the cancer and a lower risk of developing the cancer. The first benefit results 
from detection of the cancer at an early stage, since colorectal cancer is often diagnosed at a 
very late stage, which is negatively correlated with the survival probability. The second effect 
is linked to the removal of polyps, which could develop into cancer, from the colon. 
  Let us assume that an individual with colorectal cancer is treated according to standard 
procedures. Then we can define the CRTC-function for an individual as 
 
    [,(,) ;] CRTC c A T A θ τ =                        (1) 
      
where A is a continuous variable that describes the advancement of the disease, T is time alive 
from the time of diagnosis, and θ is a vector of factors that affects the time the individual 
remains alive after the diagnosis, such as age, gender and education, while τ is a vector of 
factors that affects the CRTC, such as differences in treatment procedures across hospitals. 
From (1) we see that advancement enters the CRTC function both directly and indirectly 
through the survival function. From equation (1) the change in CRTC with an increase in 
advancement is given by 
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'
A c  refers to the derivative of cost with respect to advancement,   denotes the 




A T  is the derivative of 
survival time from diagnosis with respect to advancement. 
  The above description of the various treatment procedures shows that the amount of 
treatment given to an individual increases with advancement. Given this relation we expect 
the   function to increase in accordance with advancement, i.e.   since we expect 
treating the less advanced cancers are less costly than more advanced cancers. But treatment 
for colorectal cancers can last for several years and as the survival prognosis is poorer for 
more advanced cancers, fewer resources may be spent on patients with poorer prognosis than 
on those with better prognosis because they receive less intensive treatment. If this is so, it is 
no longer given that CRT  is an unambiguous positive function in advancement. 
CRTC
' 0 A c >
C
  Since treatment lasts for several years   increases with the time the individual 
remains alive after a cancer diagnosis (survival), i.e.  . The surviving time is further 
closely related to advancement: the probability of dying is much smaller for an individual 
diagnosed with a less advanced cancer than for one with a more advanced one, i.e.  .    
CRTC
' 0 T c >
' 0 A T <
  The second part of the right hand side of equation (2) is negative, i.e. the sign of 
equation (2) is uncertain. In order to provide evidence for increasing CRTC with regard to 
advancement, the direct effect of an increase in advancement has to be positive,  . This 
condition is necessary, but not sufficient. In addition, the direct effect has to be greater than 
the indirect effect as a consequence of longer survival time (in absolute value), hence 
' 0 A c >
  
   
'' ||
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  Screening is expected to result in a decline in advancement A. If (3) holds, we would 
expect that CRTC for an asymptomatic participant in screening is smaller than the CRTC in 
the control group.  
  In the theoretical presentation it was assumed that advancement is a continuous 
variable. Colorectal cancers are often presented in stages according to advancement, where 
the stages are defined according to some discrete factors. The continuous factors like the size 
of the tumour will be included as the variation within each stage. In this paper we apply the 
Dukes staging system, which is one of the most frequently used. In this system there are four 
stages of advancement, in ascending order: 
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  Dukes A: Cancer localised within the bowel wall 
  Dukes B: Cancer which penetrates the bowel  
  Dukes C: Cancer which has spread to lymph nodes 
    Dukes D: Cancer with distant metastasis 
 
The mix of discrete and continuous factors, complicates the discussion, because a shift in the 
distribution towards less advanced cancer will affect the distribution of cancers both between 
and within Dukes stages. Shifts between stages will occur when for example screening 
implies that the category Dukes B after screening includes cancers that without screening 
would have been categorised in more advanced stages or that some cancers categorised as 
Dukes B without screening, with screening will be categorised as Dukes A. Shifts within 
stages occurs when the most advanced Dukes B cancers are categorised as less advanced 
Dukes B due to screening. The effect of screening on the distribution of Dukes C cancers 
would be similar to Dukes B. For Dukes A there is a possibility that there will be an 
accumulation of cancers in the least advanced part of Dukes A. At the same time, more 
advanced cancers will be categorised as Dukes A as a result of screening and belong to the 
more advanced part of Dukes A. In addition, as a result of screening, some carcinoma “in 
situ” will be diagnosed and treated. Carcinoma “in situ” is a group of abnormal cells that 
remain in the tissue in which they first formed. These abnormal cells may become cancer and 
spread into nearby normal tissue. Some of these would never become symptomatic and thus 
unnecessary treatment is offered. Carcinoma “in situ” cancers could be expected to shift the 
distribution within the Dukes A towards less advanced cancers. The shift for Dukes D cancers 
will unambiguously be towards less advanced cancers as cancers are entering in the upper part 
of the distribution.   
  A shift in the distribution of cancers according to advancement will change the CRTC 
for each Dukes stage if and only if the distribution of cancers according to advancement 
within each Dukes stage is affected by screening.      
  From equation (1) we see that CRTC depends on survival time, which is a function of 
not only advancement and screening, but also of individual characteristics. High age is 
generally assumed to reduce survival probability (see Fenn et al. 1996), so that, given the 
same diagnosis, an individual of 65 has a smaller probability of surviving than an individual 
who is only 55. Since women on average live longer than men (Statistics Norway 2003), we 
expect that a woman will have a higher probability of surviving than a man. Other factors also 
  6play a role here. Education level is expected to reduce the probability of dying, see Kravdal 
(2000). Survival after a diagnosis of colorectal cancer varies between counties in Norway; for 
example Oslo County has a lower survival rate than Telemark County (the Cancer Register 
2003). Life expectancy in Norway is higher than most other countries (Statistics Norway 
2003). As this study contains individuals in the age group 50 to 64 years, most of the 
immigrants are first generation. Hence, we would expect survival to be higher for individuals 
born in Norway. 
 
 
3. Empirical specification 
In our model we assume that an individual diagnosed with cancer never fully recovers. 
This is a simplification of a more dynamic approach and will be discussed in concluding 
remarks. As the individual is assumed to never fully recover, he has to be followed up until 
death. Our assessment of the full treatment cost is based on this assumption. It is not possible 
to follow individuals for such a long period in clinical trials, which means that the data are 
censored, with two exit possibilities: death and end of dataset.  
  The purpose of this study is to estimate differences in the cumulative CRTC of 
treating individuals in the total screening group or screening sub-groups and the control 
group. Building on the work of Etzioni et al. (2001), we define the expected CRTC for each 
screening group as:   
 
   [1 ( )]
D D
t t EF t =− ∑
D E               t = 0,…, S                       (4) 
 
where D refers to the total screening group or screening sub-groups and the control group, t 
denotes months after diagnosis, where t = 0 denotes the month of diagnosis,  is the 






t E is 
the average CRTC incurred in month t among all cases surviving to this time. 
D
t E  includes the 
CRTC both for individuals surviving through month t and for those dying in month t. The 
survival function is here used to estimate expected CRTC per month, thus the expected CRTC 
for a specific month is weighted by the probability of being alive in that specific month. 
Hence, the cost of a specific inpatient service is weighted less 20 months from diagnosis than 
5 months from diagnosis. Thus (4) expresses the expected CRTC. Survival can be modelled in 
several ways, where a proportional hazard model and an accelerated failure time model are 
  7two alternatives. In a proportional hazard model the coefficients relates to a proportional 
change in the hazard rate and not survival. Like Fenn et al. (1996) we apply an accelerated 
failure time model since in this model it is easier to infer directly the response of survival time 
to the independent variables. The regression coefficients relate proportionate changes in 
survival time to a marginal change in a given regressor, with all other characteristics held 
fixed. Let T denote survival time and let x be a vector of explanatory variables. Assume that  
 
  ln( ) D Tx z β =+              ( 5 )    
 
where  D β is a vector of parameters and z is an error term
1. Like Fenn et al. (1996) we assume 
furthermore that z u σ = , where  0 σ >  is a scale parameter and u is a “standardized” random 
term with cumulative distribution equal to the Weibull distribution 
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Let  1 p σ = . Then the corresponding survival function is given by 
 
   ( ) 1 ( | , ) exp( )
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1 From (5) we can find the expected survival time 
1
() ( 1 )
x D ET e
p
β =Γ + , where the  (.) Γ is the gamma function 
and equal to a constant.  The log is then given as 
1
log ( ) log (1 ) D ET x
p
β =+ Γ + .  
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where  p represent duration dependency, which can be constant (corresponding to 1 p = ), 
negative (corresponding to  ) and positive (corresponding to ). A positive duration 
dependency, implies that the probability of surviving increases over time, i.e. an individual 
who has survived for five years has a higher probability to survive to the next period than an 
individual who has survived only two years. When p  is one, the Weibull distribution is 
reduced to the exponential distribution. The hazard function is defined as the conditional 
probability of dying in the next instant of time given that the individual survived to time t, and 
is from (8) given by
1 p < 1 p >
2 
 
                       (9) 
1 ( | , ) exp( )
Dp
D ht x p p t x p β
− =−
 
Our dataset contains censored spells, since we do not follow up all the individuals 
until they die. For those still alive at the end of the observation period, we only know that the 
duration was at least  j t . Consequently, the contribution to the likelihood of this observation is 
the value of the survival function, i.e. the probability that a duration of survival is longer than 
j t . Let   if the jth spell is uncensored,  1 j d = 0 j d =  if censored. If the sample consists of n 
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  Estimating (10) for asymptomatic participants, total screening group and the control 
group would capture the effect of screening on the distribution of cancers both between and 
within Dukes stages. In this paper we are not able to estimate (10) because of a limited 
numbers of observation. It is therefore impossible to estimate separate survival functions for 
asymptomatic participants, total screening group and the control group; thus, we need to 
simplify. One alternative is to estimate a survival function for all individuals and let survival 
depend on Dukes stages, screening groups and control group and an interaction between 
 
2 The density function is the slope of the survival function in (8) and defined as: 
0
Pr( | )
(|, ) l i m
t
D
D tTt t D F
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 and the relation between the hazard function, the density 
function and survival function is defined as  (|, ) (|, ) [ 1 (|, ) ]
DD D f tx p h tx p F tx p =−  
3 See Green (2002 ) 
  9Dukes stage and group. Such an approach could reveal whether screening adds an extra effect 
to Dukes stages on survival, i.e. if screening shifts the distribution within stages. This 
estimation is also impossible because of data limitations. Two options have been considered: 
Estimating the survival function based on a pooled data sample, i.e. both screened and 
unscreened individuals, and estimating the survival function separately for the control group. 
We choose the latter first of all we then know that the results in the control group will be 
consistent. If we use the pooled data, results in both the control group and the screening 
groups can be biased. But this simplification implies that screening does not affect the 
distribution of cancers within each Dukes stage. Based on this assumption, the log likelihood 
function is   
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The basis for our study is NORCCAP (the Norwegian Colorectal Cancer Prevention, 
see Bretthauer et al. (2002)), which was carried out in Norway in the period 1999-2001.  
The choice of design for NORCCAP was influenced by a pilot study; see Hoff et al. 
(1985). NORCCAP was implemented in two counties: Telemark (165,855 inhabitants in 
2003), where the pilot study had been carried out, and Oslo (517,401 inhabitants in 2003). 
Oslo represents a typical urban area, while Telemark has both urban and rural areas. 
NORCCAP was a once-only screening, using the screening methods flexible sigmoidoscopy 
and faecal occult blood tests.
4 Half of the total screening group was offered flexible 
sigmoidoscopy and the other half a combination of flexible sigmoidoscopy and faecal occult 
blood tests. Flexible sigmoidoscopy enables the physician to examine the interior of the large 
intestine from the rectum through the distal part of the colon (about 50 cm of the total colon), 
called the sigmoid colon. This procedure makes it possible to look for adenomas,
5 and the 
presence of adenomas denotes an increased risk of developing colorectal cancer. The faecal 
occult blood test is self-administered and requires stool samples on three consecutive days. 
The samples are smeared onto chemically impregnated cards and sent to the laboratory at the 
 
4 The faecal occult blood test used here is a FlexSureOBT®, an immunochemical test for human blood. 
5 Adenomas are outgrowths in the colon. The larger they are, the more likely they are to develop into cancer. 
  10time of screening participation. The NORCCAP exclusion criteria included being treated for 
cancer and taking anticoagulants.  
Every year from 1999 to 2001, 7,000 individuals were invited (3,500 from each 
county) to participate in NORCCAP. During 1999 and 2000, individuals between 55 and 64 
were invited, and in 2001 individuals between 50 and 54 were invited. The participation rate 
for the whole period was 65 percent.  
  The dataset consists of all individuals invited to the screening (20,780) and a control 
group (79,808). The control group consists of all the remaining individuals in the same age-
group from the two counties. The dataset includes information about age, gender, education, 
county of residence, time and cause of death, and other demographic variables obtained from 
Statistics Norway. From the Cancer Registry of Norway we obtained data on incidence, time 
of diagnosis and stage of advancement at the time of diagnosis. From the National Patient 
Register we obtained information on inpatient and outpatient services at the hospitals in 
Telemark and Oslo. The total observation period is from 1999 to 2003, i.e. S=60 in equation 
(4).  
 
Table 1: Proportions of cancers distributed according to stage of advancement in  
screening subgroups and control group. Number of observations 292. 
 
Variable   
              Participants 
Asymptomatic   Symptomatic  
Non-participants Control  group 
Dukes A        0.513                 0.038  0.000  0.065 
Dukes B        0.205                 0.538  0.417  0.287 
Dukes C        0.256                 0.346  0.500  0.533 
Dukes D        0.026                 0.077  0.083  0.115 
 
 
  In the period 1999 to 2003, 450 individuals in the dataset were diagnosed with 
colorectal cancer, and it was possible to classify 292 by the Dukes staging system. Table 1 
shows the proportion of cancers according to screening subgroup and stage of advancement. 
About 75 percent of cancers detected at screening were either Dukes A or Dukes B. For 
symptomatic participants the proportion of Dukes B is higher than in the control group, while 






  11Table 2: Number of cancers from 1999 to 2003 according to screening subgroups and stage 
of advancement. Total numbers of cancers in the subgroups are reported in brackets. 
Group    During screening  After screening 
  Dukes  1999 2000 2001 2002 2003 
Asymptomatic participants (39)         
  A  5 11 4     
  B  3 2 3     
  C  2 7 1     
  D  0 1 0     
Symptomatic participants (26)         
  A  0 0 0 1 0 
  B  1 5 0 6 2 
  C  0 1 1 4 3 
  D  0 1 1 0 0 
Non-participants (12)         
  A  0 0 0 0 0 
  B  0 1 3 1 0 
  C  2 0 1 2 1 
  D  0 0 1 0 0 
Total screening group (77)         
  A  5 11 4  1  0 
  B  4 8 6 7 2 
  C  4 8 3 6 4 
  D  0 2 2 0 0 
Controls (215)         
  A  2 3 3 5 1 
  B  5 14  16  14 9 
  C  6  26 33 30 24 
  D  1 6 7 5 5 
Total screening group and controls 
(292) 
       
  A  7 14 7  6  1 
  B  9  22 22 21 11 
  C  10 34 36 36 28 
  D  1 8 9 5 5 
 
 
  In Table 2 we show the number of cancers from 1999 to 2003 according to screening 
group and stage of advancement. Since the screening was carried out from 1999 to 2001, no 
cancers are recorded among asymptomatic participants in 2002 and 2003. The number of 
cancers among symptomatic participants is, as expected, lower in the screening period (1999 
to 2001) compared with the period after the screening period: 10 and 16 cancers, respectively. 
We expect cancers among non-participants to be diagnosed later in the observation period 
than cancers among asymptomatic participants, but this is not confirmed by our study, since 
eight cancers are diagnosed during the screening period and only four afterwards. This may be 
due to the small size of the sample. The number of cancers in the total screening group is the 
sum of the cancers in the three screening subgroups.  
  12To estimate expected CRTC we use two different samples. When we analyse expected 
CRTC as a function of Dukes stages we include all cancers, i.e. that number of observations 
are 292. When we compare expected CRTC in the total screening group or screening sub-
groups with the control group, we use another sample. To ensure comparable expected CRTC 
accumulated, we include cancers diagnosed within the same period. Thus the cancers 
diagnosed from 1999 to 2001 are included since this is the period in which the screening was 
carried out. The cancers diagnosed after the screening, 2002 and 2003, are therefore excluded 
from the sample, which then is reduced to 179 observations.  
 
 
4.1 Survival  
  Out of 215 individuals diagnosed with cancer during the period 1999 to 2003, 59 died 
during the period. In the analysis we have included all deaths occurring during treatment for 
colorectal cancer. In Table 3 we show the number of cancers, number of total deaths and 
proportion of cancers and total deaths for each stage of advancement. The proportion of 
cancers or total deaths is arrived at by dividing the number of cancers diagnosed at a 
particular stage of advancement by the total number of cancers diagnosed or the total number 
of deaths, respectively. Over 50 percent of all the cancers are diagnosed at the Dukes C stage. 
Most of the total deaths occur in the Dukes C and Dukes D groups. Dukes D has the highest 




Table 3: Numbers of cancers, proportion of cancers, numbers of deaths and proportions of 
deaths according to stage of advancement. M=215. 




No of deaths  Proportion of 
deaths 
Dukes A  14  0.065  3  0.051 
Dukes B  58  0.270  3   0.051 
Dukes C  119  0.553  36  0.610 
Dukes  D  24 0.112 17 0.288 
Total 215  1.000  59  1.000 
 
  
In the control group the mean age at the time of diagnosis tends to be slightly higher 
for the individuals that are alive compared to the mean age for those who are dead, 59.6 and 
58.7, respectively. Table 4 shows the proportion dead according to the socio-economic 
variables used in the analysis. The numbers indicate that there is almost no difference in 
  13survival status for gender. There are some differences in proportion dead, and the proportion 
is higher for individuals: living in Oslo, born in a country other than Norway and having a 
low level of education. 
 
Table 4: Descriptive statistics for discrete variables according to survival status. M = 215.  
Variable Category  Dead 


















Education (years)   
Low (0-10) 
Intermediate (11-14) 







4.2 Treatment cost 
The intensity of the treatment is closely related to the advancement of the cancer. The 
treatment follows certain standard procedures (Norsk Gastrointestinal Cancer Gruppe, 1999), 
but there is room for individual variation. Colorectal cancer refers to cancer of the colon or 
the rectum. Unless the localisation is specified, our use of the term “treatment” covers both 
types. Surgery is the most common treatment for colorectal cancer. If the cancer is limited to 
a polyp, the patient can undergo a simple polypectomy (removal of the polyp), or a local 
excision, in which a small amount of surrounding tissue is also removed. If the tumour has 
invaded the bowel wall or surrounding tissues, a partial resection (removal of the cancer and a 
portion of the bowel) is necessary, together with removal of local lymph nodes to determine 
whether the cancer has spread to this area. In cases where it is not possible to reconnect the 
two parts of the colon, a colostomy (an opening in the abdominal wall to allow the passage of 
stools) is performed. Even though in a majority of patients the whole tumour seems to have 
been removed by surgery, the cancer recurs in as many as 40 percent of these patients, and 
chemotherapy is also given to reduce the risk. There is some controversy about whether 
patients with Dukes B disease should receive chemotherapy. The patients in this group who 
are considered to be at higher risk of recurrence are given chemotherapy for six to eight 
months, and the remainder are followed up closely, generally without receiving 
  14chemotherapy. Patients who present with Dukes C cancer are typically treated for 12 months. 
With regard to radiation therapy, there are differences between colon and rectal cancer. Colon 
cancer is not usually treated with radiation therapy, although this may be an option if the 
cancer has invaded another organ or adhered to the abdominal wall. Radiation therapy is an 
option for all stages of rectal cancer, but its use increases with the stage of advancement. At 
follow-up all patients are checked for recurrence. Follow-up usually entails physical 
examinations and colonoscopies. 
The aim is to measure the opportunity cost of treating colorectal cancer by means of 
information from the National Patient Register and the National Insurance Administration. 
The costs of outpatient and inpatient services are calculated from the reimbursement system. 
The cost of outpatient services is covered by fee for service, activity-based financing and 
block grants, and that of inpatient services by activity-based financing and block grants. The 
activity-based financing is based on diagnosis-related groups (DRG). The DRG system 
classifies hospital services into groups that are medically related and homogeneous with 
regard to use of resources. DRG is a way of describing the hospital’s case-mix. In Norway 
there are about 500 different DRGs. Each DRG is given a weight that reflects the treatment 
cost. For outpatient services the fee for service only partly covers the true cost. On the basis of 
a Norwegian study (Samdata somatikk, 2004) we have adjusted all the fees from the National 
Insurance Administration by a factor of 1.5 so that they better reflect the true cost. During the 
observation period the DRG weights have changed in spite of no major changes in the 
treatment for colorectal cancer. The unit price for DRG has also changed
6, but we apply the 
DRG weight and unit price for 2003 for all observation years
7. Whether fee for service, DRG 
weights and unit price reflect the opportunity cost will be discussed in more detail in the 
concluding remarks. Some of the patients were treated for other diseases during the 
observation period, but we include only costs that are directly related to the treatment of 
colorectal cancer
8. We therefore disregard any relation between the treatment of colorectal 
cancer and other diseases. A proportion of the individuals having adenomas at the screening 
were recommended to undertake a follow-up colonoscopy. As the focus in this paper is on 
expected CRTC for individuals diagnosed with colorectal cancer, other costs as a 
consequence of screening are not included here. Such costs will be included in an economic 
evaluation of the screening trial, see Aas (2007). 
                                                 
6 Changes in the unit price for DRG can be explained by for instance changes in efficiency and input prices.   
7 One DRG was in 2003 equal to EUR 3706 
8 The outpatient and inpatient services, together with the fees or DRGs and DRG weights, are shown in 
Appendix A1. 
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Table 5: Descriptive statistics for selected outpatient and inpatient services. Mean number of 
treatments  according to stage of advancement at diagnosis. Number of observations 292.  
Service  Dukes A  Dukes B  Dukes C  Dukes D 
Outpatient          
  Therapeutic colonoscopy   0.17  0.29  0.14  0.07 
  Diagnostic  colonoscopy  0.51 0.93 0.57 0.25 
  Therapeutic  sigmoidoscopy  0.17 0.01 0.03 0.00 
  Diagnostic  sigmoidoscopy 0.03 0.09 0.11 0.05 
Outpatient        
  Chemotherapy – unspecified  0.43  1.71  8.65  6.5 
  Chemotherapy – group 1  0  0.12  0.89  1.36 
  Chemotherapy – group 2   0  0  0.01  0.11 
Inpatient         
  Rectum resection with 
additional diagnosis or 
complications 
0.23 0.09 0.22 0.21 
  Rectum resection without 
additional diagnosis or 
complications 
0.17 0.21 0.13  0 
  Major surgery of the large 
intestine with additional 
diagnosis or complications 
0.14 0.28 0.39 0.54 
  Major surgery of the large 
intestine without additional 
diagnosis or complications 
0.26 0.34 0.20 0.04 
  Malignant disease in the 
gastrointestinal organs with 
additional diagnosis or 
complications 
0.03 0.13 0.39 0.68 
  Malignant disease in the 
gastrointestinal organs 
without additional diagnosis 
or complications 
0.03 0.07 0.24 0.18 
 
  Table 5 shows the most frequently used outpatient and inpatient services. The table 
illustrates variations in treatment for the different stages of advancement, and shows the 
average number of registrations per individual at each stage, i.e. the total number of 
registrations divided by the number of individuals diagnosed at each stage. There is no 
obvious relation between the proportion of patients who have undergone colonoscopy and 
stage of advancement. On the other hand there is a clear correlation between cancer stage and 
chemotherapy. An individual with Dukes B receives on average 1.83 chemotherapy 
treatments, an individual with Dukes C on average 9.55 treatments and an individual with 
Dukes D on average 7.97. An individual with Dukes C or Dukes D also tends to need more 
  16advanced surgery; 0.39 of the individuals with Dukes C and 0.54 of those with Dukes D had 
undergone extended surgery on the colon, with complications.  
 
 
5. Results of the survival analysis 
To estimate expected CRTC, we first estimate the survival function, 1-F(t), in 
equation (8) by estimating the log likelihood in (11)
9. The coefficients from the estimation are 
presented in Table 6
10. The positive signs indicate a higher probability of survival. Two 
different specifications of the model are presented in the table in order to show the stability of 
the results.  
We find that the probability of surviving declines with the stage of advancement of the 
cancer at diagnosis, as can be seen from the positive coefficients for Dukes A, B and C. The 
probability of surviving increases with the education level, since an individual with a low 
level of education is less likely to recover than an individual with long education. In general, 
recovery is supposed to depend on the waiting time from diagnosis to start of treatment, the 
treatment itself, and the individual’s general health status, spirit of determination and ability 
to make use of his knowledge about cancer. The level of education could be an indicator of 
how much the individual is able to influence these factors. For example, he can influence the 
time from diagnosis to the start of treatment by choosing a hospital with a short waiting time. 
Recovery is also likely to depend on the individual’s ability to make use of his knowledge 
about treatment to adopt behaviour that enhances the treatment.  
There are no significant differences in survival with regard to age, county of residence, 
native country or gender. The coefficients in both models are of a fairly similar magnitude 
and alter little when variables are excluded. The parameter p represents the duration 
dependency, which in the estimation is not different from one (at a five percent level); hence 
the distribution of T is exponential in x, the duration dependency is constant and the hazard 
function in (9) is constant. Given mean value of the covariates, we estimate the hazard 
function in (9) to be 5.1 per thousand.        
  The survival function is estimated and presented in Figure 1. The Figure shows that 
survival falls from 1 to about 0.62. Since only 59 out of 215 died during the period, the 
survival function will not end at zero. In order to illustrate our results better, we calculated the 
                                                 
9 The estimations were done by the use of STATA 8 
10 During the estimation we tried several distributions like Cox, generalized gamma and log-normal, but all 
estimation resulted in the same findings.   
  17hazard function for two different sub-samples by using the estimated coefficients and 
equation (9).  
 
Table 6: Regressors of survival function. M = 215. (SD in parenthesis)  
Variable  Model 1  Model 2 
Constant   2.548 (1.568)    2.701 (0.280)***  
Dukes  stage                   
(ref. Dukes D)                    A 
                                           B 









Age by diagnosis  0.002 (0.025)   
County 


















(ref. low)                             Intermediate (11–14) 













LR chi²  (p value)  53.46 (0.000)  52.16 (0.000) 
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Figure 3: The hazard rate according to stage of advancement. M=215. 
 
 
The calculations are presented in Figure 2 and Figure 3. In Figure 2 the estimated hazard 
function according to the two levels of education included in the analysis, intermediate and 
long, is presented. The figure illustrates the differences in prognosis for the two different 
levels. The hazard function for long education is lower than for intermediate education, i.e. 
  19the probability of dying in the next instant of time given that the individual is alive at time t is 
higher for an individual diagnosed with intermediate education at any point in time after the 
cancer diagnosis. After 60 months from diagnosis an individual with long education has about 
8 percent higher probability of surviving than an individual with intermediate education. 
  In Figure 3 we present the hazard function accord to stage of advancement. The hazard 
function for Dukes C is higher than both Dukes A and Dukes B, i.e. the probability of dying 
in the next instant of time given that the individual is alive at time t is higher for an individual 
diagnosed with Dukes C at any point in time after the cancer diagnosis. After 60 months from 
diagnosis an individual with Dukes A has about 14.5 percent higher probability of surviving 
than an individual with Dukes C. 
 
 
6. Colorectal treatment cost 
  In order to say something about the overall gain from screening, we have to compare 
expected CRTC for the asymptomatic participant with that for the control group. The 
differences in expected CRTC between these two groups are shown in Table 7.  
  To estimate the expected CRTC we use all the registrations directly related to the 
treatment of colorectal cancer from the National Patient Register with the appropriate fees, 
DRGs and DRG weights. The estimation is done in several steps: first, calculating treatment 
cost per registration; second, estimating total CRTC per month by adding up the treatment 
cost per registration for each month for all individuals in the stage; thirdly, estimating average 
CRTC per month by dividing total CRTC per month by the sum of individuals diagnosed with 
cancer and alive in that specific month; fourthly, estimating the expected CRTC per month by 
adjusting average CRTC per month for survival according to Dukes stages; fifthly, the costs 
are discounted at four percent rate; and finally, adding together the expected CRTC per month 
over the whole period to arrive at the expected CRTC for the screening groups and the control 
group. Predicted survival for each month according to stage of advancement is presented in 
Appendix A2. 
  The expected CRTC for a colorectal cancer diagnosed among asymptomatic 
participants is EUR 17,201 while that for a colorectal cancer in the control group is EUR 
23,568. In addition, the table shows that the expected CRTC for the total screening group is 
lower than the expected CRTC for the control group
11. The expected CRTC for a colorectal 
                                                 
11 The CRTC in the total screening group is not equal to the average of the cost for the three screening subgroups 
since the number of cancers within each group is not the same. 
  20cancer for asymptomatic participants is EUR 6,367 higher than the expected CRTC in the 
control group. In this study we have only included colorectal cancer diagnosed in the period 
1999 to 2001. In this period 68 percent of all diagnosed cancers were asymptomatic, thus the 
expected CRTC for the total screening group is affected. Including several years will reduce 
the proportion of asymptomatic cancers and thus we will expect that the expected CRTC for 
the total screening group will increase and the difference between the total screening group 
and the control group decline.  
 
 Table 7: Expected CRTC adjusted for survival according to screening groups and control 
group. Number of observations 179. Numbers in Euro (EUR 1 = NOK 8) 
   Colorectal treatment cost 
Group    Outpatient Inpatient  Total 
Participation    







  CRC after screening  4,667 13,355  18,022 
Non participation    9,295 16,224  25,519 
 
Total screening  
















To explain the results in Table 7 we present the expected CRTC for each stage of 
advancement according to screening group in Table 8. Table 8 shows that expected CRTC 
increases from Dukes A to Dukes C, but declines for Dukes D for the total screening group 
and the control group. The fall in CRTC from Dukes C to Dukes D can be explained by lower 
survival in this group. The decline in CRTC for Dukes D is smaller than the increase in CRTC 
from Dukes B to Dukes C. For asymptomatic participants there is only one observation on the 
expected CRTC for Dukes D, thus it is hard to draw conclusions about the rise in expected 
CRTC from Dukes C to Dukes D. In the control group expected CRTC for a Dukes A is 
approximately EUR 14,532, while expected CRTC for Dukes C is EUR 26,855. The largest 
increase in expected CRTC is from Dukes B to Dukes C, which is accounted for by the fact 
that the largest increase in outpatient services occurs between these two stages. We know that 
a patient with Dukes B receives less chemotherapy than a patient with Dukes C. The increase 
in expected CRTC for inpatient services is likely to be related to the need for more extensive 
and complicated surgery for a patient with Dukes C or Dukes D than for a patient with Dukes 
A or Dukes B.  
  21From Table 8 expected CRTC for each Dukes stage is also presented according to 
screening groups and control group. In this paper we have assumed that the survival according 
to Dukes stages is not affected by screening, thus we assume that the distribution of cancers 
within each Dukes stage is the same as without screening. Even though the same survival 
function has been applied to estimate expected CRTC in the screening groups and the control 
group, the expected CRTC in the screening groups could be different from the expected 
CRTC in the control group and reflect a different distribution of cancers within each Dukes 
stage. If the expected CRTC in the screening groups is the same as the expected CRTC in the 
control group, it could reflect a similar distribution of cancers within each Dukes stage, but 
not necessarily, because screening could have an effect on survival. If screening does not have 
an effect on survival, equal expected CRTC in the screening groups and the control group 
implies that the distribution within each Dukes stage is unchanged. But, if survival has an 
effect on survival, the distribution of cancers within each Dukes stage could be different even 
though expected CRTC in the screening groups and the control group are equal. When 
expected CRTC in the screening groups and the control group are different in Table 8, we can 
conclude that screening has an effect on the distribution of cancers within each Dukes stage. 
The effect on expected CRTC of screening on survival comes in addition. The effect of 
screening on survival within each Dukes stage is uncertain. If screening increases survival 
within a Dukes stage, the expected CRTC reported in Table 8 for the screening groups are too 
low, while if screening reduces survival the expected CRTC are too high. The interpretation 
of different expected CRTC between the screening groups and the control group depends on 
the distribution of expected CRTC within each Dukes stage. 
In Table 8 we see that expected CRTC for asymptomatic participants are different for 
all Dukes stages from the expected CRTC for the control group, thus it seems like screening 
affects the distribution of cancers within Dukes stages. For Dukes A the expected CRTC is 
lower for asymptomatic participants than the expected CRTC in the control group. The 
finding indicates that a Dukes A cancer for asymptomatic participants requires, on average, 
less intensive treatment than a Dukes A in the control group, thus the distribution of cancers 
within Dukes A has shifted towards less advanced cancers. Carcinomas “in situ” may partly 
explain the difference in advancement. If survival is estimated separately for the screening 
groups and the control group, the difference in expected CRTC for asymptomatic participants 
and control group could be affected. If survival for Dukes A is higher for asymptomatic 
participants, the expected CRTC for asymptomatic participants would increase and approach 
the expected CRTC for the control group.  
  22The expected CRTC for Dukes B is also lower for asymptomatic participants than for 
the control group, thus there are indications that screening affects the distribution of 
advancement within Dukes B towards less advanced cancers. A shift to less advanced cancers 
within Dukes B would be expected to increase survival for asymptomatic participants. Thus, 
the expected CRTC for Dukes B would increase if survival is adjusted for screening groups. 
The distribution within Dukes C for asymptomatic participants is shifted towards more 
advanced cancers, as the expected CRTC is higher for the asymptomatic participants than in 
the control group. If screening has a negative effect on survival within Dukes C for 
asymptomatic participants, the expected CRTC would decline if screening is included in the 
estimation of survival. For Dukes D it is expected that screening shifts the distribution 
towards less advanced cancers. This could imply more extensive treatment, as more treatment 
alternatives are possible, which can explain the finding in Table 8. The result is uncertain as it 
is based on only one observation. At the same time, the unambiguous reduction in 
advancement within the stage will imply an increase in survival. Thus the inclusion of the 
effect of screening on survival would therefore imply that the difference in expected CRTC 
between asymptomatic participants and the control group will increase.  
 
 
Table 8: Expected CRTC adjusted for survival according to stage of advancement and 
selected screening groups. N=292. Figures in euros (EUR 1 =NOK 8)   
Advancement  Screening group  Colorectal treatment cost 
   Outpatient  Inpatient  Total 
Dukes A  Asymptomatic participants 












Dukes B  Asymptomatic participants 
Total screening group 
Control group 
 









Dukes C  Asymptomatic participants 




  8,891 







Dukes D  Asymptomatic participants 
Total screening group 
Control group 
16,627 
  3,950 












  237. Sensitivity analysis 
  In the statistical model we assumed that treatment cost depends on the time the 
individual remains alive after the time of diagnosis. Since it is likely that costs vary within 
each stage of advancement, our expected CRTC estimates are uncertain. Even though there 
are guidelines for the treatment of colorectal cancer, health personnel at one hospital or within 
one hospital may have different views on the amount or type of treatment, like chemotherapy, 
necessary for a specific patient. The cost estimates are based on fees and DRGs. These are 
average estimates and in some situations do not reflect the true treatment cost for a particular 
patient. For instance, the same type of treatment according to the DRG of two individuals 
with different ages may call for a different use of resources. If the older individual recovers 
more slowly he will need a longer stay in hospital than the younger individual, a difference 
that is not necessarily reflected in the DRG. Complications due to treatment of other disease 
concurrent to treatment for colorectal cancer may also result in variations in treatment costs. 
From Table 8 there are also indications that the expected CRTC within each Dukes stage are 
affected by screening.  
  We use two different methods to account for the uncertainty in the expected CRTC 
estimates; probabilistic sensitivity analysis (PSA) and bootstrapping
12. The PSA is a 
parametric method, as we make assumptions about the distribution, while the bootstrap 
method is nonparametric. We present the results of both methods, since our conclusions are 
affected by the choice of method. Both the US panel on cost-effectiveness analysis (Gold et 
al., 1996) and the National Institute of Clinical Excellence (NICE) in the UK (2004), have 
suggested using PSA to deal with uncertainty in cost-effectiveness models because a well-
conducted PSA will provide a more realistic representation of variations in the model results. 
All uncertainty in the parameters is included simultaneously in a PSA. The uncertainty in a 
specific parameter is represented by a distribution. Because CRTC only has positive values, 
we use gamma distributions to represent uncertainty (Spiegelhalter et al., 2004). We then use 
a Monte Carlo simulation to estimate the uncertainty in the parameters by selecting values 
from the distributions. Inferences from the cost estimates in the model are summarized in 
Appendix A3, and Table A5 and A6. The parameters are estimated by using the distribution 
of CRTC estimates for all individuals within each group (according to stage of advancement 
or total screening group and control group). From these distributions we derive the mean and 
variance, which we use in the estimation of the parameters. Monte Carlo simulation in 
                                                 
12 One-way sensitivity analysis and Tornado diagrams are alternative sensitivity analyses, but are not included as 
uncertainty is not directly related to specific variables for in-patient services.      
  24TreeAge recalculates the model repeatedly as a form of (deterministic) sensitivity analysis. 
We assume that the parameters are independent.  
  Bootstrapping is a method for assigning measures of accuracy to statistical estimates, 
in the present case the expected CRTC estimates. We use bootstrapping to estimate the 
standard error (see Efron and Thibshirani 1993) of the expected CRTC as shown in Tables 7 
and 8. The bootstrap standard error is estimated by using the original samples. A bootstrap 
sample of CRTC for Dukes C (n = 144) is obtained by random sampling n times, with 
replacement, from the original sample, which means that some of the observations will be 
sampled once, others several times and some not at all. The method generates a large number 
of bootstrap samples, each of size n. We reapply the estimator (for instance the CRTC for 
Dukes C) from each bootstrap sample and calculate the standard deviation.  
  The results of the Monte Carlo simulation and bootstrapping are shown in Table 9. As 
a consequence of the broad distribution of CRTC estimates within asymptomatic participants, 
the total screening and the control group and within each stage of advancement (shown in 
Appendix A3), the width of the gamma distributions in the PSA is large, and the 95 percent 
confidence intervals therefore overlap. However, we also show the proportion of 
recalculations that rank the expected CRTC for a specific group in the simulation. The 
confidence intervals of the asymptomatic participants and the control group overlap, but in 
about 69 percent of the simulations the control group is ranked with the highest expected 
CRTC. In about 83 percent of the simulations either Dukes C or Dukes D is ranked with the 
highest CRTC despite the fact that the confidence intervals are wide. The 95 percent 
confidence intervals with the bootstrap method are smaller. Due to random sampling with 
replacement, extreme values (both high and low) are given less weight than in the PSA, where 
the extreme values are included in the estimation of variance. Table 9 shows that according to 
the bootstrap method the expected CRTC for the asymptomatic participants is lower than 
expected CRTC in the control group, while the expected CRTC for the total screening group 
slightly overlap the confidence interval for the control group. These findings show that there 
is a reduction in the CRTC function. The expected CRTC for Dukes A is significantly 
different from the CRTC for Dukes C and Dukes D. The CRTC for Dukes C is significantly 
higher than the CRTC for Dukes A and Dukes B, but not significantly different from the 
CRTC for Dukes D.  
 
 
  25Table 9: Expected CRTC and PSA with 95% confidence intervals, and proportions of 
recalculations where the Dukes stage is ranked with the highest CRTC according to the PSA 
and bootstrap method, with 95% confidence intervals. Figures represent cost in Euros. 




       Bootstrap        
 
Asymptomatic participants  17,736  (4,629 – 38,832)  0.312  (13,779 – 20,953) 
Total screening group  18,492  (4,744 – 42,902)    (15,435 – 21,669) 
Control group   24,006  (6,917 – 62,906)  0.688  (21,194 – 26,568) 
        
Dukes A  11,779  (2,406 – 28,712)  0.046  (9,741 – 15,595) 
Dukes B  15,470  (3,735 – 36,505)  0.126  (13,844 – 18,226) 
Dukes C  26,656  (7,249 – 70,678)  0.454  (23,653 – 29,150) 
Dukes D  23,282  (6,917 – 59,588)  0.374  (18,377 – 26,538) 
 
 
8. Concluding remarks 
In this paper we have examined whether screening results in a reduction in the 
treatment cost for colorectal cancer, because such a reduction would be an incentive for the 
insurer to invest in screening. Since the purpose of screening is to reduce the proportion of 
advanced cancers, a reduction in the treatment cost can be expected to occur if colorectal 
cancer treatment cost is an increasing function of the advancement of the cancer. Colorectal 
cancer treatment cost is estimated as a function of advancement and adjusted for survival. Our 
findings show that the colorectal cancer treatment cost not unambiguously increase with 
advancement at the time of diagnosis. Still, we find that the expected colorectal treatment cost 
for asymptomatic participants are lower than that for the control group. This finding is 
favourable with regard to investing in screening, but total screening costs and health effects 
need to be evaluated before a conclusion on investing in screening can be drawn.  
We know that colorectal cancer treatment cost estimates are uncertain. The 
probabilistic sensitivity analysis gives overlapping 95 percent confidence intervals for the four 
stages of advancement of the cancer and between the asymptomatic participants, total 
screening group and the control group. Despite these wide intervals, about 69 percent of the 
simulations ranked the control group as having a higher cost than the asymptomatic 
participants. In about 83 percent of the simulations the two most advanced stages were ranked 
as having the highest colorectal treatment cost. The PSA is a parametric method which 
assumes that the variation in treatment cost between individuals can be represented by a 
specific distribution. This is a strong assumption; we therefore also used the bootstrap 
method, which is a non-parametric method. The 95 percent confidence intervals with the 
bootstrap method are narrower, and there are significant differences in relation to the PSA in 
  26the colorectal treatment cost between the asymptomatic participants and the control group. In 
addition there are differenced in the treatment cost between the two least advanced cancer 
stages and the two most advanced.    
The estimates of the survival function show that the probability of surviving declines 
with stage of advancement and increases with the level of education. Estimates derived from 
the Weibull model show that the duration dependency is not different from one; hence the 
hazard rate is constant.   
From the estimation of Equation (11) we find that the survival after 5 years is 0.75, 
0.85, 0.55 and 0.13 for Dukes’ A to D respectively (see A2 for details). Tveit et al. (1996) 
find survival to vary from 0.80 – 0.90 (for Dukes’ A and B) to less than 0.05 for Dukes D. 
This indicates that survival is overestimated in our models for all groups, but especially for 
Dukes’ D. There are at least two explanations for this overestimation. Firstly, only about 7 
percent of the cancers are diagnosed in 1999 (first year of observations) and have a five years 
duration. This may cause uncertainty in the estimation of survival. Secondly, only 292 out of 
450 cancers are categorised according to the Dukes staging system. If the cancers used in the 
analysis not represent the distribution of cancers, the expected colorectal treatment cost will 
be biased and expected colorectal treatment cost and survival could be affected. If advanced 
cancers within each stage are underrepresented in the sample, it would imply that survival is 
overestimated. A decline in survival will imply a reduction in the expected colorectal 
treatment cost. If the reduction in the expected colorectal treatment cost is lager for Dukes D 
than for the other Dukes categories, the conclusion in Section 6 can change. But, a larger 
proportion of advanced cancers also implies more intensive treatment and increased expected 
colorectal treatment cost. The total effect of the bias on expected colorectal treatment cost for 
each Dukes stage is therefore uncertain.  
If the 215 cancers in the control group with stage description do not represent the 
distribution of cancers between stages, the expected colorectal treatment cost could be 
affected. In Tveit et al. (1996) the distribution of cancers according to Dukes stages is 
reported to be: Dukes A – 10 percent, Dukes B – percent, Dukes C – 35 percent and Dukes D 
– 25 percent. From the distribution of cancers in Table 1, the data set used in this paper 
includes too few Dukes A and Dukes D, too many Dukes C, and the same proportion of 
Dukes B. Given the estimated expected colorectal treatment cost for each Dukes stage in 
Table 8, the expected colorectal treatment cost for the control group would decline if we had 
applied a distribution of cancers according to Tveit et al. (1996).     
  27In Table 2 the number of cancers is recorded according to stage of advancement and 
screening groups. The number of cancers among non-participants is 12 with stage description, 
which is about 30 percent of all cancers diagnosed among non-participants during the period. 
In the control group about 60 percent of all cancers could be categorised in the Dukes stage 
system. According to the discussion above, including all cases could change the expected 
colorectal treatment cost. In future research it would be interesting to analyse if expected 
colorectal treatment cost for non-participants changes when all cancers are included.     
We know from the discussion in Section 6 that screening seems to affect the 
distribution of cancers within each Dukes stage, although a firm conclusion is not possible 
because not all relevant data are collected. The first choice of analysis would be to estimate 
expected colorectal treatment cost separately for the screening groups and the control group 
based on equation (10). Then it would be possible to determine whether Dukes stages have a 
different effect on survival for asymptomatic participants and for the control group. If there 
are differences, the expected colorectal treatment cost could be adjusted for survival for the 
specific screening group. The expected colorectal treatment cost would then capture changes 
in the distribution of cancers within Dukes stages that both change the intensity of treatment 
and survival. We would then have the best estimate on expected colorectal treatment cost.      
In this paper we base the survival analysis on data from the control group in 
NORCCAP. Even though this group consists of approximately 80 000 persons, the sample is 
still small. To reduce the uncertainty, estimation of survival in the control group could have 
been based on register data from the Cancer Registry of Norway. Using register data would 
not solve the problem with categorising the cancers according to the Dukes staging system. In 
order to solve the last problem, applying another staging system should be considered in 
future research. Data on colorectal cancer treatment cost is based on data from the National 
Patient Register and NORCCAP because general permission was not given to merge data 
from the National Patient Register with other registers.  
We assume in the model that the individual never fully recovers from colorectal 
cancer and has to be followed up until death in order to get the full treatment cost. Since the 
observation period is five years, 1999 to 2003, and only 59 out of 215 died during this period, 
the expected colorectal cancer treatment cost can be higher. It is possible to estimate expected 
colorectal cancer treatment cost beyond the observation period. Together with estimates of 
future colorectal cancer treatment cost per month we can use the survival model to predict 
future survival probability. We believe that prediction is unnecessary as most recurrences 
appear within four to five years after the diagnosis. In table 10 the expected colorectal cancer 
  28treatment cost per year is reported. The expected colorectal cancer treatment cost is at the 
highest in the first year and drop to zero or almost zero the fifth year.   
 
Table 10: Expected colorectal cancer treatment cost according to stage of advancement and 
year from diagnosis. Figures present costs in Euro. M=179.  
Category  Year 1  Year 2  Year 3  Year 4  Year 5 
Dukes A  12,211     607  1,818      162  128 
Dukes B  14,435  2,159  1,106      622    38 
Dukes C  22,510  5,782  2,948   3,160     0 
Dukes D  20,994  3,257            298        7     0 
 
  The purpose of screening is to detect, treat and prevent cancer earlier in the cancer 
progression than would normally occur with symptomatic diagnosis and thus achieve a lead-
time to prolong life expectancy. Lead-time bias occurs when screening falsely prolongs 
survival. Then the individual gains no additional life-years as the time for diagnosis has only 
been moved forward. The patient's awareness of having cancer and level of anxiety will be 
extended causing a reduction in quality of life. In this analysis, lead time bias with regard to 
survival is not relevant here as survival is based on data for the control group. But, if the 
survival function is estimated for each screening group, the result could be affected by lead 
time bias. 
  The effect of lead-time on treatment intensity is captured in the analysis. Lead-time 
implies that all cancers are less severe at the time of diagnosis. Some of these cancers may 
need less intensive treatment as asymptomatic and not symptomatic. For instance it could be 
that the asymptomatic diagnosed cancers do not qualify for chemotherapy. In this situation the 
expected colorectal cancer treatment cost will be reduced. But, early diagnosis could also 
imply more intensive treatment, because the cancers are severe and thus qualify for more 
intensive treatment, for instance surgical procedures or more extensive chemotherapy. More 
extensive treatment will increase expected colorectal cancer treatment cost. If lead-time is 
most likely to increase expected colorectal treatment costs, the expected colorectal cancer 
treatment costs according to Dukes stages should be adjusted downwards. From Table 8 we 
see that there is a tendency for lead-time to imply a reduction for Dukes A and Dukes B, 
while it implies an increase for Dukes C and Dukes D.  
  The data from the National Patient Register do not contain information about radiation 
therapy, which is mainly used in the treatment of rectal cancer. We do not believe that this 
lack of data changes the conclusion that screening reduces colorectal cancer treatment cost, 
since the amount of radiation therapy increases with severity. The lack of data will only result 
in underestimation of colorectal cancer cost.  
  29  The aim of the present study was to measure the opportunity cost of treating colorectal 
cancer. The opportunity cost of an input can be measured by the value of its best alternative 
use. In this study we use DRG-cost and fee for service as measures for opportunity cost, thus 
the question is whether these measures reflect the true opportunity cost. Both DRG-cost and 
fee for service are cost estimates of the resource use in the treatment of colorectal cancer, of 
which labour is the main resource. An increase in the number of treatments of colorectal 
cancer results in increased input of labour. If there is no unemployment, the increase in labour 
will be labour that already is employed. Since the gross wage rate can be interpreted as a 
minimum estimate of the employer’s willingness to pay for the labour, the wage rate is 
interpreted as a minimum estimate of the opportunity cost. If the opportunity cost is higher 
than the estimates we use in our study, the differences in the colorectal cancer treatment cost 
according to stage of advancement will be greater. Hence the absolute value of the reduction 
in colorectal cancer treatment cost from screening will also be greater.  
  This paper presents the first step of a cost-effectiveness analysis of a once-only 
screening for colorectal cancer, based on a randomized controlled trial (RCT). The present 
RCT provides us with a useful instrument for analysing whether screening influence the cost 
of treating the disease in question, which in this study is colorectal cancer. Treatment of 
cancer is usually extensive and costly; thus interventions that could reduce future costs are of 
great interest for the government as insurer. However, the CRTC is only one factor in the total 
cost function. The total cost function (Meltzer, 1997, Garber and Phelps, 1997, Weinstein, 
M.C. and W.G. Manning, 1997 and Johannesson and Meltzer, 1998) also includes costs 
related to the screening, production loss and future treatment costs. Two cost components are 
relevant with regard to this paper: As a consequence of screening, some individuals with 
adenomas receive a recommendation for a follow-up colonoscopy. Follow-up colonoscopies 
will increase the cost consequences of introducing screening, but not the expected colorectal 
cancer treatment costs. Further, in this analysis, cancers “in situ” result in a lower expected 
colorectal cancer treatment cost for Dukes A cancers. In a cost-effectiveness analysis 
detection of cancers “in situ” will imply an increased probability of being diagnosed with 
colorectal cancer. Hence, total costs will increase due to unnecessary treatment. The total cost 
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  32Appendix 
A1: Out-patent fees, DRG codes and DRG weights 
  
Table A1: Outpatient services with fee codes, fees (EUR 1 =NOK 7.91).  
Fee code  Procedure   Fee (EUR) 
  INTERNAL MEDICINE AND SUBSPECIALTIES 
 
 
A01   Simple  examination  8 
A02   Complete  examination  28 
   Gastroenterology   
  A10a  Ultrasound examination   56 
  A10b  Simple secretion and absorbtion examinations   56 
      
 A11a  Esophagus  manometry  90 
 A11b  Diagnostic  gastroduodenoscopy  90 
 A11c  Diagnostic  sigmoideoscopy  90 
 A11d  Therapeutic  gastroduodenoscopy  90 
      
 A12a  Therapeutic  colonoscopy  152 
  A12b  24 hours PH-monitoring of esophagus   152 
  A12c  Extensive absorption and secretion examination by means of 
radioactive isotop 
152 
 A12d  Diagnostic  colonoscopy  152 
 A12e  Therapeutic  sigmoideoscopy  152 
  A12f  ERCP with radiographic guidance  152 
  A12g  Endoscopic ultrasound examination with flexible endoscope, incl. 
videotaping  
152 
      
   Surgical specialities   
B01   Simple  examination  8 
B02   Complete  examination  28 
   General surgery   
  B03a  Removal of mammary tumor, skin tumour, lymph nodes, etc.  56 
  B03b  Removal of deep foreign objects   56 
 B03c  Simple  wound  treatment  56 
  B03d  Incision and drainage of abscess  56 
  B03e  Anoskopy with string ligature of haemorrhoids  56 
      
 B04a  Extensive  wound  treatment  90 
  33      
   Oncology   
H01   Simple  examination  8 
H02   Complete  examination  28 
      
  H03a  Punction cytology for representative sampling  56 
  H03b  Removal of acsites  56 
 H03c  Removal  of  hydrothorax  56 
  H03d  Telephonic counselling of non-hospital doctors about oncology 
treatment at home or in another institution  
56 
      
  H04a  Blood or plasma transfusion incl. necessary tests, blood typing and test 
of crossmatch   
90 
 H04b  Socio-medical  evaluation by means of psychiatrist, social worker or 
ergotherapeut 
90 
  H04c  Psychosocial evaluation, palliative measures and follow-up of patients 
in collaboration with interdisciplinary team associated with oncology 
department  
90 
  H04d  Oncologic therapy in the patient’s home or other locations outside the 
hospital. 
90 
      
  H05a  Intravenous infusion of particularly toxic cytostatics   0 
 H05b  Intravesical  chemotherapy  0 
  H05c  External radiation, per area  83 
  H05d  Treatment of pain by means of anaesthesiologist, oncologist or nurse  83 
      
  H06a  Interstitial radiation therapy  152 
  H06b  Sociomedical evaluation and treatment of cancer patients  152 
  H06e  Lengthy consultation (> 1 hour)  152 
  H06c  Photodynamic therapy of skin cancer, per lesion  106 









  34Table A2: Outpatient services, DRG codes and DRG weights 
DRG code  Procedure  DRG weight 
410 A  Chemotherapy, unspecified  0.18 
410 B  Chemotherapy, group 1  0.32 
 
 
Table A3: Inpatient services, DRG codes and DRG weights (ac: additional diagnosis or 
complication) 
DRG code  Procedure  DRG weight 
78  Pulmonary embolism, air embolism, fatty embolism  1.52 
89  Pneumonia and pleuritis age 18+ with ac  1.53 
128 Deep  thrombophlebitis  0.9 
146  Rectum resection with ac  4 
147  Rectum resection without ac  3.08 
148  Major surgery of the colon with ac  4.29 
149  Major surgery of the colon without ac  2.54 
152  Minor operation on the small intestine or colon with ac  2 
153  Minor operation on the small intestine or colon without ac  1.34 
157  Minor intestinal surgery and surgery on anus and colostomy with ac  1.18 
158  Minor intestinal surgery and surgery on anus and colostomy without ac  0.58 
170  Surgery of gastrointestinal organs ITAD with ac  2.85 
171  Surgery of gastrointestinal organs ITAD without ac  1.38 
172  Malignant disease of the gastrointestinal organs with ac  1.24 
173  Malignant disease of the gastrointestinal organs without ac  0.9 
416  Sepsicaemia with diseases of main diagnosis group 18, age 18+  1.81 
418  Postoperative & posttraumatic infections related to main diagnosis group 
18  0.83 



















  35A2. Predicted survival for each month 
Table A4: Predicted survival according to stage of advancement. Number of observations 
215. 
Month  Dukes A  Dukes B  Dukes C  Dukes D 
1  1.0000 1.0000 1.0000 1.0000 
2  0.9952 0.9973 0.9900 0.9660 
3  0.9904 0.9946 0.9801 0.9332 
4  0.9857 0.9919 0.9703 0.9014 
5  0.9809 0.9892 0.9606 0.8708 
6  0.9762 0.9866 0.9510 0.8412 
7  0.9715 0.9839 0.9415 0.8126 
8  0.9669 0.9813 0.9321 0.7849 
9  0.9622 0.9786 0.9227 0.7583 
10  0.9576 0.9760 0.9135 0.7325 
11  0.9530 0.9733 0.9044 0.7076 
12  0.9484 0.9707 0.8953 0.6835 
13  0.9439 0.9681 0.8864 0.6603 
14  0.9394 0.9655 0.8775 0.6378 
15  0.9349 0.9629 0.8687 0.6161 
16  0.9304 0.9603 0.8601 0.5952 
17  0.9259 0.9577 0.8515 0.5750 
18  0.9215 0.9551 0.8429 0.5554 
19  0.9170 0.9525 0.8345 0.5365 
20  0.9126 0.9499 0.8262 0.5183 
21  0.9083 0.9474 0.8179 0.5007 
22  0.9039 0.9448 0.8097 0.4836 
23  0.8996 0.9423 0.8016 0.4672 
24  0.8952 0.9397 0.7936 0.4513 
25  0.8909 0.9372 0.7857 0.4360 
26  0.8867 0.9346 0.7778 0.4211 
27  0.8824 0.9321 0.7700 0.4068 
28  0.8782 0.9296 0.7623 0.3930 
29  0.8740 0.9271 0.7547 0.3796 
30  0.8698 0.9246 0.7472 0.3667 
31  0.8656 0.9221 0.7397 0.3543 
32  0.8614 0.9196 0.7323 0.3422 
33  0.8573 0.9171 0.7250 0.3306 
34  0.8532 0.9146 0.7177 0.3193 
35  0.8491 0.9122 0.7106 0.3085 
36  0.8450 0.9097 0.7034 0.2980 
37  0.8410 0.9073 0.6964 0.2879 
38  0.8369 0.9048 0.6894 0.2781 
39  0.8329 0.9024 0.6826 0.2686 
40  0.8289 0.8999 0.6757 0.2595 
41  0.8249 0.8975 0.6690 0.2507 
42  0.8210 0.8951 0.6623 0.2421 
43  0.8170 0.8927 0.6557 0.2339 
44  0.8131 0.8902 0.6491 0.2260 
45  0.8092 0.8878 0.6426 0.2183 
46  0.8053 0.8854 0.6362 0.2108 
47  0.8015 0.8831 0.6298 0.2037 
48  0.7976 0.8807 0.6235 0.1968 
49  0.7938 0.8783 0.6173 0.1901 
50  0.7900 0.8759 0.6111 0.1836 
51  0.7862 0.8736 0.6050 0.1774 
52  0.7824 0.8712 0.5990 0.1713 
53  0.7786 0.8688 0.5930 0.1655 
54  0.7749 0.8665 0.5870 0.1599 
  3655  0.7712 0.8642 0.5812 0.1544 
56  0.7675 0.8618 0.5754 0.1492 
57  0.7638 0.8595 0.5696 0.1441 
58  0.7601 0.8572 0.5639 0.1392 
59  0.7565 0.8549 0.5583 0.1345 
60  0.7529 0.8526 0.5527 0.1299 
 
 
A3. Assumptions in the probabilistic sensitivity analysis 
α and λ can be estimated from the gamma distribution using the following two definitions: 
α = mean²/variance 
λ = mean/variance  
 
Table A5: Assumptions in the probabilistic sensitivity analysis ranking the four stages of 
advancement. Mean and variance are reported in NOK. Number of observations 292.  
Dukes   Treatment costs:  Mean  Variance 




    4,139 
112,117 
 
  (2,506)² 
(87,184)² 





























Table A6: Assumptions in the probabilistic sensitivity analysis ranking the screening group 
and the control group. Mean and variance are reported in NOK. Number of observations 179. 



























  53,940 
134,596 
 
(90,887)² 
(63,197)² 
 
  37